Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 2/20 | 0.45 |
| ▸ | AURKA | O14965 | 2/20 | 0.44 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.44 |
| ▸ | TDO2 | P48775 | 1/20 | 0.44 |
| ▸ | JAK2 | O60674 | 5/20 | 0.43 |
| ▸ | JAK3 | P52333 | 5/20 | 0.43 |
| ▸ | JAK1 | P23458 | 4/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | TYK2 | P29597 | 2/20 | 0.42 |
| ▸ | SYK | P43405 | 2/20 | 0.42 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | IGF1R | P08069 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3344180 | 0.90 | NPC1 (0.53) | NPC1RAB9ASMN1; SMN2EGFRAURKA | |
| SCHEMBL3450656 | 0.89 | MAPK1 (0.49) | NPC1RAB9ASMN1; SMN2EGFRTDO2 | |
| SCHEMBL3452065 | 0.85 | IRAK4 (0.42) | FGFR1NPC1RAB9ASMN1; SMN2EGFR | |
| SCHEMBL3450341 | 0.84 | MAPK1 (0.46) | EGFRJAK3MAPK1 | |
| SCHEMBL3449764 | 0.83 | MAPK1 (0.51) | NPC1RAB9ASMN1; SMN2EGFRMAPK1 | |
| SCHEMBL3452720 | 0.83 | MAPK1 (0.51) | NPC1RAB9ASMN1; SMN2EGFRJAK3 | |
| SCHEMBL3450023 | 0.82 | MAPK1 (0.50) | EGFRJAK3MAPK1 | |
| SCHEMBL3449638 | 0.82 | MAPK1 (0.50) | EGFRJAK3MAPK1 | |
| SCHEMBL3451168 | 0.82 | MAPK1 (0.44) | NPC1RAB9ASMN1; SMN2EGFRMAPK1 | |
| SCHEMBL3447770 | 0.81 | NPC1 (0.56) | NPC1RAB9ASMN1; SMN2JAK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | SDHA, SDHB, UROD | FGFR1 3917/4885NPC1 603/4885RAB9A 2449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.